TY - JOUR
T1 - Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study)
AU - Calegari, Maria Alessandra
AU - Salvatore, Lisa
AU - Di Stefano, Brunella
AU - Basso, Michele
AU - Orlandi, Armando
AU - Boccaccino, Alessandra
AU - Lombardo, Fiorella
AU - Auriemma, Alessandra
AU - Zurlo, Ina Valeria
AU - Bensi, Maria
AU - Camarda, Floriana
AU - Ribelli, Marta
AU - Vivolo, Raffaella
AU - Cocomazzi, Alessandra
AU - Pozzo, Carmelo
AU - Milella, Michele
AU - Martini, Maurizio
AU - Bria, Emilio
AU - Tortora, Giampaolo
PY - 2021
Y1 - 2021
N2 - Recently, retrospective analysis began to shed light on metastatic colorectal cancers (mCRCs) harboring rare BRAF non-V600 mutations, documenting a distinct phenotype and a favorable prognosis. This study aimed to confirm features and prognosis of rare BRAF non-V600 mCRCs compared to BRAF V600E and BRAF wild-type mCRCs treated at two Italian Institutions. Overall, 537 cases were retrospectively evaluated: 221 RAS/BRAF wild-type, 261 RAS mutated, 46 BRAF V600E and 9 BRAF non-V600. Compared to BRAF V600E mCRC, BRAF non-V600 mCRC were more frequently left-sided, had a lower tumor burden and displayed a lower grade and an MMR proficient/MSS status. In addition, non-V600 mCRC patients underwent more frequently to resection of metastases with radical intent. Median overall survival (mOS) was significantly longer in the non-V600 compared to the V600E group. At multivariate analysis, only age < 65 years and ECOG PS 0 were identified as independent predictors of better OS. BRAF V600E mCRCs showed a statistically significant worse mOS when compared to BRAF wild-type mCRCs, whereas no significant difference was observed between BRAF non-V600 and BRAF wild-type mCRCs. Our study corroborates available evidence concerning incidence, clinicopathologic characteristics and prognosis of BRAF-mutated mCRCs.
AB - Recently, retrospective analysis began to shed light on metastatic colorectal cancers (mCRCs) harboring rare BRAF non-V600 mutations, documenting a distinct phenotype and a favorable prognosis. This study aimed to confirm features and prognosis of rare BRAF non-V600 mCRCs compared to BRAF V600E and BRAF wild-type mCRCs treated at two Italian Institutions. Overall, 537 cases were retrospectively evaluated: 221 RAS/BRAF wild-type, 261 RAS mutated, 46 BRAF V600E and 9 BRAF non-V600. Compared to BRAF V600E mCRC, BRAF non-V600 mCRC were more frequently left-sided, had a lower tumor burden and displayed a lower grade and an MMR proficient/MSS status. In addition, non-V600 mCRC patients underwent more frequently to resection of metastases with radical intent. Median overall survival (mOS) was significantly longer in the non-V600 compared to the V600E group. At multivariate analysis, only age < 65 years and ECOG PS 0 were identified as independent predictors of better OS. BRAF V600E mCRCs showed a statistically significant worse mOS when compared to BRAF wild-type mCRCs, whereas no significant difference was observed between BRAF non-V600 and BRAF wild-type mCRCs. Our study corroborates available evidence concerning incidence, clinicopathologic characteristics and prognosis of BRAF-mutated mCRCs.
KW - BRAF
KW - Metastatic colorectal cancer
KW - Molecular profile
KW - Non-V600
KW - Rare mutation
KW - V600E
KW - BRAF
KW - Metastatic colorectal cancer
KW - Molecular profile
KW - Non-V600
KW - Rare mutation
KW - V600E
UR - http://hdl.handle.net/10807/205797
U2 - 10.3390/cancers13092098
DO - 10.3390/cancers13092098
M3 - Article
SN - 2072-6694
VL - 13
SP - 1
EP - 13
JO - Cancers
JF - Cancers
ER -
